Filana Therapeutics (FLNA) Receivables (2010 - 2020)

Filana Therapeutics (FLNA) posted quarterly Receivables of $86000.0 for Q3 2020, down 62.77% quarter-over-quarter from $231000.0 in Q3 2011.

Filana Therapeutics (FLNA) Receivables (2010 - 2020) Analysis & Trends

Filana Therapeutics' Receivables history runs 3 years deep, the most recent figure standing at $86000.0 for Q3 2020.

In Q3 2020, Receivables changed N/A year-over-year to $86000.0; the TTM figure through Sep 2020 stood at $86000.0 (changed N/A YoY), while the FY2010 annual figure was $7.1 million, changed N/A from the prior year.
Receivables for Q3 2020 stood at $86000.0, down from $231000.0 in the prior quarter.
The five-year high for Receivables was $86000.0 in Q3 2020, with the low at $86000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.18 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.98 Bn	77.98 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.37 Bn	59.19 Bn	1.37 Bn	1.93 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.75 Bn	9.35 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.24 Bn	26.08 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.03 Bn	26.20 Bn	-	-
10	Filana Therapeutics	45.71 Mn	45.71 Mn	-	-

Download Data